Firm claims urology-focused acquisition will transform it from pharma company to diversified physician partner.!--h2>
Endo Pharmaceuticals is buying urological products and services firm HealthTronics for $223 million in cash plus the assumption of around $35 million in debt. Endo said the acquisition will provide it with new urology products including benign prostatic hyperplasia and prostate cancer therapies, as well as lithotripsy and anatomical pathology services for the diagnosis and detection of cancer and other diseases.
Endo focuses on the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for the treatment and management of pain, bladder cancer, prostate cancer, and the early onset of puberty in children.
The firm said that acquiring HealthTronics will diversify its revenue base and boost its position as a provider of multiple medical solutions and delivery mechanisms in urology. “This strategic acquisition immediately elevates Endo from a pharmaceutical company to a diversified partner to physicians and payers in the treatment and diagnosis of urological and pain-related conditions,” stated Dave Holveck, president and CEO.